Top 10 Lemborexant (Dayvigo) Generic Manufacturers in India
The global prescription sleeping aids market has been witnessing significant growth, driven by increasing incidences of insomnia and other sleep disorders. In India, the pharmaceutical market is valued at approximately $42 billion as of 2022, with a compound annual growth rate (CAGR) of 11.5% projected through 2025. With the recent patent expiration of Lemborexant (Dayvigo), several Indian manufacturers are gearing up to produce generics to meet the rising demand. This report highlights the top 10 manufacturers in India that are poised to dominate the Lemborexant generic market.
1. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical is one of the largest pharmaceutical companies in India, with a market share of around 7.5%. The company produces a wide range of generic medications, including Lemborexant, leveraging its robust R&D capabilities. Sun Pharma’s production volume exceeds 1,000 tons annually.
2. Cipla Ltd.
Cipla is a leading player in the Indian pharmaceutical market, with a significant focus on generics. The company’s revenue from generics has reached approximately $3 billion, contributing to its extensive portfolio that includes Lemborexant. Cipla’s manufacturing facilities are compliant with international quality standards, ensuring high production volumes.
3. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is known for its strong pipeline of generic drugs, including Lemborexant. The company reported revenues of about $2.5 billion in 2022, with generics contributing significantly. Its advanced manufacturing technologies enable high-quality production and compliance with global standards.
4. Zydus Cadila
Zydus Cadila is a prominent player in the Indian pharmaceutical sector, boasting a market share of around 6%. The company has a diverse range of products, including generics of Lemborexant. Zydus Cadila operates multiple manufacturing sites, ensuring a production capacity of over 800 tons annually.
5. Aurobindo Pharma
Aurobindo Pharma is a major manufacturer of generics and reported a revenue of approximately $3.5 billion in 2022. The company’s manufacturing facilities are well-equipped, and it is positioned to produce Lemborexant effectively, with a focus on quality and compliance.
6. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals has a diverse portfolio and is recognized for its innovation in generics. With revenues nearing $1.5 billion, the company has invested significantly in R&D to support the production of Lemborexant. Glenmark’s production capacity stands at around 500 tons annually.
7. Torrent Pharmaceuticals
Torrent Pharmaceuticals specializes in branded and generic formulations, with a significant share in the Indian market. The company reported revenues of about $1.3 billion in 2022. Torrent’s production facilities are equipped to manufacture Lemborexant while adhering to high-quality standards.
8. Alkem Laboratories
Alkem Laboratories is known for its robust generics portfolio and reported sales of approximately $1.4 billion. The company has established a strong presence in various therapeutic segments, including sleep disorders, and is well-positioned to manufacture Lemborexant.
9. Mylan (now part of Viatris)
Mylan, now part of Viatris, has a strong foothold in the generic pharmaceuticals market, with extensive production capabilities. The company’s generics are well-received, contributing to its revenue of nearly $11.5 billion in 2022. Mylan is gearing up to produce Lemborexant to meet market demands.
10. Hetero Drugs
Hetero Drugs is a significant player in the Indian pharmaceutical industry, focusing on affordable generics. The company reported revenues of around $1 billion, with a commitment to high-quality production. Hetero is preparing to launch its Lemborexant generics soon.
Insights and Forecasts
The market for Lemborexant generics in India is expected to expand significantly as the demand for effective sleep aids rises. With the increasing prevalence of sleep disorders, the generics segment is projected to grow at a CAGR of 15% through 2027. The market size for sleep medications in India is anticipated to reach approximately $1.2 billion by 2025. The competitive landscape is likely to intensify as more manufacturers enter the Lemborexant market, leading to price reductions and improved accessibility for patients. Furthermore, collaboration between manufacturers and healthcare providers will be critical in driving awareness and adoption of generic Lemborexant products.
Related Analysis: View Previous Industry Report
